Success Stories: A Postdoctoral Fellow Secured both her EB1-A and NIW Approvals in the Field of Genetics with our Persistent Support

Client’s Testimonial:

“My EB2-NIW and EB1-A cases were approved with the help from Chen Immigration. They are professional, patient and easy to communicate with. I strongly recommend Chen Immigration to anyone applying for EB1-A and EB2-NIW.”

On January 6^th, 2022 and April 19^th, 2022, we received another EB-1A (Alien of Extraordinary Ability) and EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Fellow in the Field of Genetics (Approval Notice).

General Field: Genetics

Position at the Time of Case Filing: Postdoctoral Fellow

Country of Origin: China

State of Residence at the Time of Filing: New York

Approval Notice Date: January 6^th, 2022 (EB-1A) and April 19^th, 2022 (NIW)

Processing Time: 31 days (EB-1A) (Premium Processing Requested) and 13 months, 11 days (NIW)

Case Summary:

A petition for an employment-based immigration visa under the second preference (“EB-2”), unlike the first preference category of individuals with extraordinary ability, (“EB1-A”), at least requires:

No specific job offer/labor certification is required for a foreign person as long as he/she is entering the United States to continue work in the field in which he/she has an extraordinary ability, therefore self-petition is allowed.
Evidence of original contributions, usually through publication, of major significance in the foreign national’s field of science, scholastic, artistic, or athletic.
Performance in a significant role for organizations or establishments that have a distinguished reputation.
Receipt of a higher salary or remuneration than is usual in the field.
Other comparable evidence if the above types of evidence do not readily apply to the foreign national’s occupation.

Therefore, when a postdoctoral fellow from China holding a Ph.D. in genetics approached us to file both her EB1-A and I-140 NIW petitions, we assimilated the following essentials from her academic and professional records:

Her cell biology and biomedical informatics research address some of our nation’s and the world’s most pressing issues, including the growth of hardy crops and the treatment of hearing loss. She is particularly well-known for her contributions to the comparative transcriptome profiling of chilling stress responsiveness in two contrasting rice genotypes.
Her research has resulted in 17 peer-reviewed journal articles and 1 conference paper, being cited 398 times in at least 37 countries according to Google Scholar.
She has conducted at least 17 reviews for at least 7 journals.

Therefore, our client’s unique and expansive expertise has enabled her to contribute significantly to the field of genetics, extending the reasonable expectation that she will continue to do so within the United States.

4 fellow experts in the field provided further comprehension of the importance of her ongoing work in the field, one of whom stated:

“[Client’s] has identified a number of the genetic mechanisms involved in the functional development of the mammalian auditory system. In doing so, she has markedly accelerated the development of targeted therapeutics to combat hearing loss…These statistics illustrate the significant need for [client’s] continued genetics research related to human audition.”

Consequently, she not only received her NIW approval with the help of our teammates but even acquired her EB1-A (Alien of Extraordinary Ability) approval in just 31 days (thanks to premium processing). We are glad to have had the opportunity to represent her in this case and wish her good fortune and a prosperous future.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.